These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38072962)

  • 81. Progress on the Application of Bortezomib and Bortezomib-Based Nanoformulations.
    Liu J; Zhao R; Jiang X; Li Z; Zhang B
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053199
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Engineered nanomedicine for myeloma and bone microenvironment targeting.
    Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
    Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
    Besse L; Kraus M; Besse A; Driessen C; Tarantino I
    Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
    [TBL] [Abstract][Full Text] [Related]  

  • 84. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
    Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
    Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Bortezomib induces cellular senescence in A549 lung cancer cells by stimulating telomere shortening.
    Wang L; Yin H; Huang S; Huang S; Huang C; Zhang Z; Liu H
    Hum Exp Toxicol; 2022; 41():9603271221124094. PubMed ID: 36401358
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
    Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
    Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
    [TBL] [Abstract][Full Text] [Related]  

  • 87. A novel alkaloid compound, DCZ0358, exerts significant antitumor activity in bortezomib-resistant multiple myeloma cells through inhibition of JAK2/STAT3 pathway.
    Zhang B; Li B; Xie Y; Chang S; Xu Z; Hu H; Chen G; Zhang T; He J; Wu X; Zhu H; Lai W; Song D; Lu Y; Jia X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2023 Feb; 55(2):215-224. PubMed ID: 36815376
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Mechanisms underlying synergism between circularized tumor necrosis factor-related apoptosis inducing ligand and bortezomib in bortezomib-sensitive or -resistant myeloma cells.
    Leng Y; Hu X; Li L; Nkwocha J; Satta T; Sharma K; Kmeiciak M; Zhou H; Zhang Z; Zhou L; Chen W; Grant S
    Hematol Oncol; 2022 Dec; 40(5):999-1008. PubMed ID: 35789025
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.
    Li C; Hu J; Li W; Song G; Shen J
    Biomater Sci; 2016 Dec; 5(1):77-88. PubMed ID: 27822577
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Low expression of neural cell adhesion molecule, CD56, is associated with low efficacy of bortezomib plus dexamethasone therapy in multiple myeloma.
    Yoshida T; Ri M; Kinoshita S; Narita T; Totani H; Ashour R; Ito A; Kusumoto S; Ishida T; Komatsu H; Iida S
    PLoS One; 2018; 13(5):e0196780. PubMed ID: 29738534
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib.
    Camiolo G; Barbato A; Giallongo C; Vicario N; Romano A; Parrinello NL; Parenti R; Sandoval JC; García-Moreno D; Lazzarino G; Avola R; Palumbo GA; Mulero V; Li Volti G; Tibullo D; Di Raimondo F
    Redox Biol; 2020 Sep; 36():101611. PubMed ID: 32863212
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Bortezomib-loaded mixed micelles realize a "three-in-one" effect for enhanced breast cancer treatment.
    Liu J; Xu X; Li Y; Xu J; Zhao R; Liu S; Wu J; Zhang L; Zhang B
    Biomater Sci; 2023 Jul; 11(14):4890-4906. PubMed ID: 37306225
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Utilization of Lipid-based Nanoparticles to Improve the Therapeutic Benefits of Bortezomib.
    Korani M; Korani S; Zendehdel E; Jaafari MR; Sathyapalan T; Sahebkar A
    Anticancer Agents Med Chem; 2020; 20(6):643-650. PubMed ID: 31985384
    [TBL] [Abstract][Full Text] [Related]  

  • 94. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p.
    Pan Y; Zhang Y; Liu W; Huang Y; Shen X; Jing R; Pu J; Wang X; Ju S; Cong H; Chen H
    Cell Death Dis; 2019 Feb; 10(2):106. PubMed ID: 30728351
    [TBL] [Abstract][Full Text] [Related]  

  • 95. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib.
    Tang S; Zhang F; Li J; Dong H; Yang Q; Liu J; Fu Y
    Chem Biol Interact; 2023 Oct; 384():110687. PubMed ID: 37657595
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells.
    Roeten MSF; van Meerloo J; Kwidama ZJ; Ter Huizen G; Segerink WH; Zweegman S; Kaspers GJL; Jansen G; Cloos J
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802801
    [TBL] [Abstract][Full Text] [Related]  

  • 97. BDNF/TrkB confers bortezomib resistance in multiple myeloma by inducing BRINP3.
    Bao L; Wang Y; Lu M; Shi L; Chu B; Gao S
    Biochim Biophys Acta Gen Subj; 2023 Mar; 1867(3):130299. PubMed ID: 36565997
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Clarithromycin overcomes stromal cell-mediated drug resistance against proteasome inhibitors in myeloma cells via autophagy flux blockage leading to high NOXA expression.
    Moriya S; Kazama H; Hino H; Takano N; Hiramoto M; Aizawa S; Miyazawa K
    PLoS One; 2023; 18(12):e0295273. PubMed ID: 38039297
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Bortezomib-encapsulated metal-phenolic nanoparticles for intracellular drug delivery.
    Zhou H; Xu H; Man J; Wang G
    RSC Adv; 2024 Aug; 14(36):26176-26182. PubMed ID: 39161451
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Preparation and characterization of nanoliposomal bortezomib formulations and evaluation of their anti-cancer efficacy in mice bearing C26 colon carcinoma and B16F0 melanoma.
    Korani M; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
    Nanomedicine; 2019 Aug; 20():102013. PubMed ID: 31103736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.